MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 317388 | Name: Cefmenoxime HCl
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cefmenoxime Hydrochloride is a cephalosporin antibiotic that is administered intravenously or intramuscularly. It is active against most common gram-positive and gram-negative microorganisms, is a potent inhibitor of Enterobacteriaceae, and is highly resistant to hydrolysis by beta-lactamases. The bactericidal activity of cefmenoxime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs).The drug has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.

Chemical Structure

Cefmenoxime HCl
CAS#75738-58-8 (HCl)

Theoretical Analysis

MedKoo Cat#: 317388

Name: Cefmenoxime HCl

CAS#: 75738-58-8 (HCl)

Chemical Formula: C32H35ClN18O10S6

Exact Mass: 0.0000

Molecular Weight: 1059.56

Elemental Analysis: C, 36.27; H, 3.33; Cl, 3.35; N, 23.80; O, 15.10; S, 18.15

Price and Availability

Size Price Availability Quantity
50mg USD 350.00 2 Weeks
100mg USD 550.00 2 Week
500mg USD 950.00 2 Weeks
1g USD 1,450.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
75738-58-8 (HCl) 65085-01-0 (free base) 65085-02-1 (sodium)
Synonym
Cefmenoxime HCl; Cefmenoxime hydrochloride; SCE 1365; SCE-1365; SCE1365; AB 50912; AB50912; AB-50912;
IUPAC/Chemical Name
(6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hemihydrochloride
InChi Key
MPTNDTIREFCQLK-UNVJPQNDSA-N
InChi Code
InChI=1S/2C16H17N9O5S3.ClH/c2*1-24-16(20-22-23-24)33-4-6-3-31-13-9(12(27)25(13)10(6)14(28)29)19-11(26)8(21-30-2)7-5-32-15(17)18-7;/h2*5,9,13H,3-4H2,1-2H3,(H2,17,18)(H,19,26)(H,28,29);1H/b2*21-8-;/t2*9-,13-;/m11./s1
SMILES Code
O=C(C1=C(CS[C@@]([H])(N1C2=O)[C@@H]2NC(/C(C3=CSC(N)=N3)=N\OC)=O)CSC4=NN=NN4C)O.O=C(C5=C(CS[C@@]([H])(N5C6=O)[C@@H]6NC(/C(C7=CSC(N)=N7)=N\OC)=O)CSC8=NN=NN8C)O.Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,059.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Ren X, Liu D, Ding N, Huang K, Xiong Y, Du G, Zeng F. Safety evaluation of cephalosporins based on utilization and adverse drug events: analysis of two databases in China. Expert Opin Drug Saf. 2012 Sep;11(5):689-97. doi: 10.1517/14740338.2012.699037. Epub 2012 Jun 19. PubMed PMID: 22708900. 2: Totsuka N, Koide R. [The effect of preoperative topical antibiotics in cataract surgery]. Nippon Ganka Gakkai Zasshi. 2006 Jul;110(7):504-10. Japanese. PubMed PMID: 16884070. 3: Suzuki T, Ohashi Y. Combination effect of antibiotics against bacteria isolated from keratitis using fractional inhibitory concentration index. Cornea. 2013 Jul;32(7):e156-60. doi: 10.1097/ICO.0b013e31828ffe0e. PubMed PMID: 23665643. 4: Eicken A, Schöber JG, Roos R, Machka K. Cerebrospinal fluid penetration of cefmenoxime in children with bacterial meningitis. Infection. 1991 Nov-Dec;19(6):406-8. PubMed PMID: 1816111. 5: Onks DL, Harris JF, Robertson AF. Cefmenoxime and bilirubin: competition for albumin binding. Pharmacol Toxicol. 1991 May;68(5):329-31. PubMed PMID: 1946178. 6: Duncker G, Beigel A, Schmidt F, Ullmann U, Walpuski Y. [Cefmenoxime penetration in human lacrimal sac mucosa after systemic administration]. Fortschr Ophthalmol. 1991;88(6):861-4. German. PubMed PMID: 1794822. 7: Doi R, Inoue K, Hara K, Tobe T. Levels of cefmenoxime in sera and peritoneal tissues of patients undergoing gastrointestinal surgery. Antimicrob Agents Chemother. 1992 Jul;36(7):1483-6. PubMed PMID: 1510444; PubMed Central PMCID: PMC191608. 8: Fukuda M, Sasaki K. [Antibiotic ophthalmic solutions evaluated by pharmacokinetic parameters of maximum concentration in the aqueous]. Nippon Ganka Gakkai Zasshi. 2002 Apr;106(4):195-200. Japanese. PubMed PMID: 11979978. 9: Ayaki M, Iwasawa A, Niwano Y. In vitro assessment of the cytotoxicity of six topical antibiotics to four cultured ocular surface cell lines. Biocontrol Sci. 2012 Jun;17(2):93-9. PubMed PMID: 22790846. 10: Ikeda Y, Nishino T, Tanino T. Paradoxical antibacterial activity of cefmenoxime against Proteus vulgaris. Antimicrob Agents Chemother. 1987 Jun;31(6):865-9. PubMed PMID: 3304155; PubMed Central PMCID: PMC284201. 11: Kim KS. Efficacy of cefmenoxime in experimental group B streptococcal bacteraemia and meningitis. J Antimicrob Chemother. 1986 Feb;17(2):239-44. PubMed PMID: 3516964. 12: Tan JS, File TM Jr. Cefmenoxime versus cefoxitin in the treatment of serious bacterial infections. Am J Med. 1984 Dec 21;77(6A):51-2. PubMed PMID: 6097125. 13: Daschner FD, Petersen EE, Frank U, Hornig D. Penetration of cefmenoxime into serum, gynecologic tissues, and heart valves. Am J Med. 1984 Dec 21;77(6A):4-6. PubMed PMID: 6097123. 14: Matsumoto K, Nagatake T, Uzuka Y, Harada T, Rikitomi N. Laboratory evaluation of cefmenoxime: a new cephalosporin. In vitro and in vivo antibacterial activities and pharmacokinetic properties. Chemotherapy. 1983;29(2):80-8. PubMed PMID: 6301776. 15: Yamazaki I, Shirakawa Y, Fugono T. Comparison of the renal excretory mechanisms of cefmenoxime and other cephalosporins: effect of para-aminohippurate on renal clearance and intrarenal distribution of cephalosporins in rabbits. J Antibiot (Tokyo). 1981 Nov;34(11):1476-85. PubMed PMID: 6274834. 16: Yamazaki I, Shirakawa Y, Fugono T. Comparison of the renal excretory mechanisms of cefmenoxime and other cephalosporins: renal clearance in rats and rabbits. J Antibiot (Tokyo). 1981 Aug;34(8):1055-63. PubMed PMID: 6274837. 17: Tsuchiya K, Kondo M, Kida M, Nakao M, Iwahi T, Nishi T, Noji Y, Takeuchi M, Nozaki Y. Cefmenoxime (SCE-1365), a novel broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities. Antimicrob Agents Chemother. 1981 Jan;19(1):56-65. PubMed PMID: 6941742; PubMed Central PMCID: PMC181357. 18: Tsuchiya K, Kita Y, Yamazaki I, Kondo M, Noji Y, Fugono T. Absorption, distribution and excretion of cefmenoxime (SCE-1365), a novel broad-spectrum cephalosporin, in mice, rats, rabbits and dogs. J Antibiot (Tokyo). 1980 Dec;33(12):1532-44. PubMed PMID: 6941956. 19: Paladino JA, Fell RE. Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia. Ann Pharmacother. 1994 Mar;28(3):384-9. PubMed PMID: 8193431. 20: Masuyoshi S, Hiraoka M, Inoue M, Tomatsu K, Hirano M, Mitsuhashi S. Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime. Drugs Exp Clin Res. 1989;15(1):1-10. PubMed PMID: 2663406.